Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Metastatic Urothelial Carcinoma Clinical Trial

Official title:
A Phase I Two-Dimensional Dose-Finding Study of Ixazomib in Combination With Gemcitabine and Doxorubicin, Followed by a Phase II Extension to Assess the Efficacy of This Combination in Metastatic, Surgically Unresectable Urothelial Cancer

Status Active, not recruiting

Clinical Trial Summary

This phase I/II trial studies the side effects and best dose of ixazomib citrate, gemcitabine hydrochloride, and doxorubicin hydrochloride when given together in treating patients with urothelial cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery. Ixazomib citrate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as gemcitabine hydrochloride and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ixazomib citrate together with gemcitabine hydrochloride and doxorubicin hydrochloride may be a better treatment for urothelial cancer.

Clinical Trial Description

PRIMARY OBJECTIVE: I. Find maximum tolerated doses (MTDs) for the combination therapy of ixazomib (ixazomib citrate) and gemcitabine (gemcitabine hydrochloride)/doxorubicin (doxorubicin hydrochloride) (i.e. dose pairs of ixazomib and gemcitabine/doxorubicin that have an acceptable target toxicity rate of 30%). (Phase I) SECONDARY OBJECTIVES: I. Define the dose-limiting toxicities of the dose pairs found. II. Choose a dose pair for phase II expansion in patients with locally advanced or metastatic urothelial cancer. III. Determine the objective response rate and median survival for patients treated on the phase II expansion. OUTLINE: This is a phase I, dose-escalation study followed by a phase II study. Patients receive ixazomib citrate orally (PO), gemcitabine hydrochloride intravenously (IV) over 90 minutes, and doxorubicin hydrochloride IV over 15-30 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. ;

Study Design

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Transitional Cell
Metastatic Urothelial Carcinoma
Transitional Cell Carcinoma
Unresectable Transitional Cell Carcinoma

Clinical Trial Details

NCT number	NCT02420847
Study type	Interventional
Source	M.D. Anderson Cancer Center
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	July 3, 2015
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05700344` - SOGUG-AVELUMAB_RWD
Recruiting	`NCT04623502` - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy	N/A
Recruiting	`NCT05107674` - A Study of NX-1607 in Adults With Advanced Malignancies	Phase 1
Recruiting	`NCT04953104` - Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression	Phase 2
Withdrawn	`NCT06050954` - A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)	Phase 2
Active, not recruiting	`NCT03534804` - Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma	Phase 2
Active, not recruiting	`NCT00365157` - Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction	Phase 1/Phase 2
Withdrawn	`NCT06018116` - A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.	Phase 2
Recruiting	`NCT05544552` - Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations	Phase 1/Phase 2
Recruiting	`NCT04936230` - Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer	Phase 2
Active, not recruiting	`NCT04514484` - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Phase 1
Terminated	`NCT05052372` - Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Terminated	`NCT03115801` - A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers	Phase 2
Active, not recruiting	`NCT03854474` - Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma	Phase 1/Phase 2
Terminated	`NCT02693717` - Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer	Phase 2
Recruiting	`NCT04848519` - Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma	Phase 2
Active, not recruiting	`NCT04724018` - Sacituzumab Govitecan Plus EV in Metastatic UC	Phase 1
Terminated	`NCT04003610` - Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)	Phase 2
Recruiting	`NCT04383067` - A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients	Phase 2
Not yet recruiting	`NCT03108261` - Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations	Phase 2